Evidence map›Paper›PMID 27790981›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Tilting the balance between RNA interference and replication eradicates Leishmania RNA virus 1 and mitigates the inflammatory response.

Erin A Brettmann, Jahangheer S Shaik, Haroun Zangger, Lon-Fye Lye, F Matthew Kuhlmann, Natalia S Akopyants, Dayna M Oschwald, Katherine L Owens, Suzanne M Hickerson, Catherine Ronet and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Non-coding RNAs as emerging players inFrontiers in cellular and infection microbiology · 2025
    Article
  3. Article
  4. Novel detection ofParasitology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Analyses ofViruses · 2021
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Erin A BrettmannDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.
Jahangheer S ShaikDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.
Haroun ZanggerDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland.
Lon-Fye LyeDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.
F Matthew KuhlmannDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Natalia S AkopyantsDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.
Dayna M OschwaldGenome Technology Access Center, Washington University School of Medicine, St. Louis, MO 63110.
Katherine L OwensDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.
Suzanne M HickersonDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.
Catherine RonetDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland.
Nicolas FaselDepartment of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland.
Stephen M BeverleyDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110; stephen.beverley@wustl.edu.ORCID 0000-0001-5319-0811
Washington University in St. Louis · USUniversity of Lausanne · CH

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
MOLECULAR GENETICS OF LEISHMANIA USING DNA TRANSFECTIONR01AI029646 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 1990 to 2015
$9.3M
Leishmania RNA virus (LRV) infectivity and host responsesR56AI099364 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 2013 to 2013
$493k
NCATS NIH HHS UL1 TR000448NCI NIH HHS P30 CA091842NIAID NIH HHS R01 AI029646NIAID NIH HHS R56 AI099364
6 · The paper itself

Abstract

Many Leishmania (Viannia) parasites harbor the double-stranded RNA virus Leishmania RNA virus 1 (LRV1), which has been associated with increased disease severity in animal models and humans and with drug treatment failures in humans. Remarkably, LRV1 survives in the presence of an active RNAi pathway, which in many organisms controls RNA viruses. We found significant levels (0.4 to 2.5%) of small RNAs derived from LRV1 in both Leishmania braziliensis and Leishmania guyanensis, mapping across both strands and with properties consistent with Dicer-mediated cleavage of the dsRNA genome. LRV1 lacks cis- or trans-acting RNAi inhibitory activities, suggesting that virus retention must be maintained by a balance between RNAi activity and LRV1 replication. To tilt this balance toward elimination, we targeted LRV1 using long-hairpin/stem-loop constructs similar to those effective against chromosomal genes. LRV1 was completely eliminated, at high efficiency, accompanied by a massive overproduction of LRV1-specific siRNAs, representing as much as 87% of the total. For both L. braziliensis and L. guyanensis, RNAi-derived LRV1-negative lines were no longer able to induce a Toll-like receptor 3-dependent hyperinflammatory cytokine response in infected macrophages. We demonstrate in vitro a role for LRV1 in virulence of L. braziliensis, the Leishmania species responsible for the vast majority of mucocutaneous leishmaniasis cases. These findings establish a targeted method for elimination of LRV1, and potentially of other Leishmania viruses, which will facilitate mechanistic dissection of the role of LRV1-mediated virulence. Moreover, our data establish a third paradigm for RNAi-viral relationships in evolution: one of balance rather than elimination.

Indexed as

AnimalsAntiprotozoal AgentsGene ExpressionInverted Repeat SequencesLeishmania braziliensisLeishmania guyanensisLeishmaniasis, MucocutaneousLeishmaniavirusMacrophagesMiceOligoribonucleotides, AntisenseRNA, Double-StrandedRNA InterferenceRNA, ViralSymbiosisToll-Like Receptor 3Antiprotozoal AgentsOligoribonucleotides, AntisenseRNA, Double-StrandedRNA, ViralTLR3 protein, mouseToll-Like Receptor 3dsRNA virusendosymbiontmicrobial pathogenesisprotozoan parasitetrypanosomatid protozoa

Identifiers

PMID27790981
PMCPMC5087061
OpenAlexW2533242780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.